Aptar Increases Quarterly Dividend to $0.50 Per Share October 29th, 2026|Business Wire| CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–Aptar Increases Quarterly Dividend to $0.50 Per Share Please leave this field empty Subscribe to Our Newsletter We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information. Please check your Inbox or Spam folder now to confirm your subscription. Like this post? Share it! FacebookXLinkedInEmail Related Posts Best’s Market Segment Report: Health and Property Lines of Business Drive Hong Kong’s Non-Life Insurance Growth November 8th, 2026 | 0 Comments Alight Appoints Vikram Kalra as India Country Leader to Advance Global Delivery and Transformation November 8th, 2026 | 0 Comments Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta November 8th, 2026 | 0 Comments Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data November 8th, 2026 | 0 Comments Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss November 8th, 2026 | 0 Comments Fresh & Ready Foods LLC Recalls Fresh To You Brand Sausage, Egg & Cheese Biscuit Sandwich Due to Possible Health Risk November 8th, 2026 | 0 Comments HSS Study Highlights Potential for CAR T-Cell Therapy to Transform Lupus Treatment November 8th, 2026 | 0 Comments Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates November 7th, 2026 | 0 Comments PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026 November 7th, 2026 | 0 Comments Aqtual Presents Data Linking Blood-Based Biomarkers to Tissue Biology and Treatment Response in Rheumatoid Arthritis November 7th, 2026 | 0 Comments New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System November 7th, 2026 | 0 Comments Lilly and Hims & Hers expand access to FDA-approved Lilly medicines November 6th, 2026 | 0 Comments
